17 AAG inhibition of DBM2 tumor growth. (A) 17AAG at 60 mg/kg-d inhibits DBM2 subcutaneous tumor growth. DBM2 cells were inoculated into the flanks of nude mice at 5 × 105 cells in 100 ul PBS. After 2 weeks, mice with size-matched tumors (100 – 200 mm3) were assigned into control and treatment (60 mg/kg-d) groups (n = 19) and treatment started. Error bar represents for standard error. (B) 17AAG at 60 mg/kg-d inhibits DBM2 orthotopic tumor growth. DBM2 cells were inoculated intracranially into nude mice at 5 × 105 cells in 5 ul PBS. The tumor growth was monitored by Ultrasound. After 2 weeks, size-matched tumors were grouped into control and treatment groups (n = 10). Fold change of tumor volume = Weekly measured tumor size/Initial tumor size upon grouping. (C) The survival time of nude mice bearing orthotopic DBM2 tumor xenografts treated with 17AAG. DBM2 cells were inoculated intracranially of nude mice at 5 × 105 cells in 5 ul PBS. After 3 weeks, size-matched tumors were grouped into control (n = 6) and 2 treatment groups (20 mg/kg, 60 mg/kg, n = 8). The arrow points to the day treatment started after orthotopic tumor inoculation. Treatment was administered until individual mice became moribund according to IACUC guild-line and survival time was recorded.